Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct

Int J Pharm. 2008 May 1;355(1-2):307-13. doi: 10.1016/j.ijpharm.2007.12.007. Epub 2007 Dec 17.

Abstract

Solid lipid nanoparticles (SLNs) were prepared with a combination of homolipid from goat (goat fat) and phospholipid, and evaluated for diclofenac sodium (DNa) delivery to the eye using bio-engineered human cornea, produced from immortalized human corneal endothelial cells (HENC), stromal fibroblasts and epithelial cells CEPI 17 CL 4. Encapsulation efficiency was high and sustained release of DNa and high permeation through the bio-engineered cornea were achieved. Results obtained in this work showed that permeation of DNa through the cornea construct was improved by formulation as SLN modified with phospholipid.

MeSH terms

  • Algorithms
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Biological Transport, Active
  • Calorimetry, Differential Scanning
  • Chemistry, Pharmaceutical
  • Chromatography, High Pressure Liquid
  • Cornea / metabolism*
  • Diclofenac / administration & dosage*
  • Drug Compounding
  • Eye / metabolism*
  • Humans
  • Lipids
  • Nanoparticles*
  • Particle Size
  • Permeability
  • Solubility
  • Tissue Engineering
  • X-Ray Diffraction

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Lipids
  • Diclofenac